Business · 16/02/2005Updated: 10/17/2026 · 1 min read
FDA's Cellular, Tissue and Gene Therapies Advisory Committee to Review Amendment of Notice
Summary
The FDA's Cellular, Tissue and Gene Therapies Advisory Committee will review an amendment to a notice, following a request from the agency to update the guidance for biological response modifiers
Original source language: Federal Register — Food and Drug AdministrationOpen original release →